Journal of Clinical Apheresis最新文献

Nurse-Led Apheresis Service in a Pediatric Restructured Hospital: The Past, the Present, and the Future

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-02-20 DOI: 10.1002/jca.70009

Pham Thi Ngoc Anh, Xinni Zhong, Siew Ling Yvonne Lim, Puaness Wari Periakaruppan, Vijayakumari K.

引用次数: 0

Therapeutic Plasma Exchange in Tandem With Other Types of Extracorporeal Circuits: The Experience of a Pediatric Center and a Review of Other Pediatric Center Reports

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-02-18 DOI: 10.1002/jca.70007

Lejla Music Aplenc, Nicole Wood, Nazia Tabassum Iqbal, Cindy George, Cherie Burroughsscanlon

{"title":"Therapeutic Plasma Exchange in Tandem With Other Types of Extracorporeal Circuits: The Experience of a Pediatric Center and a Review of Other Pediatric Center Reports","authors":"Lejla Music Aplenc, Nicole Wood, Nazia Tabassum Iqbal, Cindy George, Cherie Burroughsscanlon","doi":"10.1002/jca.70007","DOIUrl":"https://doi.org/10.1002/jca.70007","url":null,"abstract":"<div>\u0000 \u0000 <p>Therapeutic plasma exchange (TPE) concurrently performed in critically ill pediatric patients with other extracorporeal circuits is a complex process. We sought to characterize tandem procedures, including patient demographics, primary diagnosis, American Society for Apheresis (ASFA) category indications, survival at 24 h and 30 days after completion, blood product utilization, and complications. A retrospective analysis of medical records was performed. Data were collected from July 2014 to January 2021 with institutional review board approval. Patients' demographics, blood product utilization, and adverse events data were collected. In addition, we performed a literature review to identify studies in the pediatric population that were similar in design to our study. Fifty patients underwent 262 procedures. The median age was 9 years, and median weight was 21 kg (42% of patients weighed less than 10 kg). The most frequent indications for plasma exchange included sepsis with multiorgan failure (11 patients) and multiorgan failure (9 patients). ASFA indication category III was the most common (42 patients), followed by uncategorized indications (6 patients). The most common adverse events were hypocalcemia, occurring in 120 (45%) procedures, hypotension in 25 (9.5%) procedures, and circuit clotting in 12 (4.5%) procedures. Citrate, heparin, and bivalirudin were used as anticoagulants. Thirty-nine (78%) patients survived 24 h, and 26 (52%) patients were alive 30 days after completion of tandem procedures. Despite the high level of complexity, tandem procedures can be performed efficiently and safely in critically ill children.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergic Reaction to Alteplase Dwell in Chronic Automated Red Cell Exchange Patient

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-02-06 DOI: 10.1002/jca.70008

R. Jacob, M. Tran, T. Sommers, T. Lee

{"title":"Allergic Reaction to Alteplase Dwell in Chronic Automated Red Cell Exchange Patient","authors":"R. Jacob, M. Tran, T. Sommers, T. Lee","doi":"10.1002/jca.70008","DOIUrl":"https://doi.org/10.1002/jca.70008","url":null,"abstract":"<div>\u0000 \u0000 <p>Allergic reactions to intravenous, alteplase have been reported, usually in doses utilized for thrombolysis. Alteplase is also widely used for clearance of occluded catheter lumens, but allergic reactions have not been reported for this route of administration. A 14-year-old patient with sickle cell disease presented with an occluded apheresis port. During alteplase dwell for port occlusion, he developed an initial reaction concerning for anaphylaxis prior to automated red cell exchange, resulting in hospitalization. Findings included angioedema to the tongue and lip as well as urticaria on his abdomen and over a previous port scar, which became warm and firm. Of note, the patient also has a history of severe atopy, uncontrolled eczema, asthma, allergic rhinitis, and elevated eosinophils. The patient was referred to allergy and a skin test to alteplase was negative. The patient underwent an alteplase challenge through his catheter where he experienced anaphylaxis. Despite appropriate treatment, he again required inpatient admission. Post reaction serum tryptase level was not elevated. A clear temporal relationship to alteplase exposure and subsequent allergic reaction was documented in this case. To our knowledge, this is the first reported case of allergic reaction to intraluminal alteplase used for clearance of an occluded apheresis port. The non-elevated tryptase level suggests a non-IgE mediated reaction. Allergic reaction to alteplase dwell for clearance of occluded lumens can occur and is an entity apheresis providers should be aware of. Additionally, traditional skin testing may not be entirely predictive of safety upon rechallenge.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of DPMAS in Patients With Acute-on-Chronic Liver Failure Based on Different Platelet Count Levels 基于不同血小板计数水平的DPMAS治疗急慢性肝衰竭患者的安全性和有效性

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-01-19 DOI: 10.1002/jca.70006

Lingyun Niu, Jiamei Zhou, Ninghui Zhao, Aiqing Zhang, Qing Ye, Jia Lian, Baiguo Xu, Jing Wen, Jia Yao, Tao Han

{"title":"Safety and Efficacy of DPMAS in Patients With Acute-on-Chronic Liver Failure Based on Different Platelet Count Levels","authors":"Lingyun Niu, Jiamei Zhou, Ninghui Zhao, Aiqing Zhang, Qing Ye, Jia Lian, Baiguo Xu, Jing Wen, Jia Yao, Tao Han","doi":"10.1002/jca.70006","DOIUrl":"10.1002/jca.70006","url":null,"abstract":"<div>\u0000 \u0000 <p>To investigate the effect of different platelet (PLT) counts on the safety and efficacy of the double-plasma molecular absorption system (DPMAS) in patients with acute-on-chronic liver failure (ACLF). A total of 156 patients with ACLF receiving DPMAS were divided into the observed group (40 × 10<sup>9</sup>/L ≤ PLT < 50 × 10<sup>9</sup>/L) and the control group (PLT ≥ 50 × 10<sup>9</sup>/L) according to PLT count level. The safety and efficacy indices of bleeding-related complications, PLT reduction rate, total bilirubin (TBIL) reduction rate, and 28-days survival rate after DPMAS were analyzed and compared between the two groups. The incidence of bleeding complications during and after DPMAS in the observed and control groups (14.3% vs. 14.9%, <i>p</i> = 0.922), the decline rate of PLT immediately and 24 h after treatment (0.13 vs. 0.11/0.05 vs. 0.09, <i>p</i> = 0.256/0.161), and the 28-days survival rate after treatment (76.2% vs. 75.4%, <i>p</i> = 0.923) were not significantly different. The thromboelastogram before DPMAS showed no significant difference in PLT function between the two groups (<i>p</i> > 0.05). Although the TBIL level of the two groups rebounded 24 h after treatment compared with immediately after treatment, it decreased significantly immediately and 24 h after treatment compared with pre-treatment levels (<i>p</i> < 0.05). There was no significant difference in the rate of decline of serum TBIL immediately after treatment and 24 h after treatment between the two groups (0.33 vs. 0.35/0.14 vs. 0.16, <i>p</i> = 0.193 and 0.653, respectively). DPMAS is safe and effective in patients with ACLF with 40 × 10<sup>9</sup>/L ≤ PLT count < 50 × 10<sup>9</sup>/L.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Legendary Case of Factitious Disorder Presenting as ‘Sickle Cell Disease’ Creates Challenges for All Medical Specialties 人为失调的传奇案例呈现为“镰状细胞病”为所有医学专业带来挑战。

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-01-14 DOI: 10.1002/jca.70005

Olivia Iverson, Theresa N. Kinard, Jeffrey L. Winters, Lance A. Williams III

引用次数: 0

Successful Use of a Midline Catheter for Leukapheresis in Patients Undergoing Collection for Immune Effector Cell Therapy, Donor Lymphocyte Infusion, and Hematopoietic Progenitor Cell Collection 在接受免疫效应细胞治疗、供体淋巴细胞输注和造血祖细胞收集的患者中成功使用中线导管进行白细胞摘除术。

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2025-01-14 DOI: 10.1002/jca.70004

Rajat Bansal, Anthony Wiedel, Riley Hastings, Fred Boutz, Haitham Abdelhakim, Nausheen Ahmed, Muhammad Umair Mushtaq, Joseph McGuirk, Sunil Abhyankar

{"title":"Successful Use of a Midline Catheter for Leukapheresis in Patients Undergoing Collection for Immune Effector Cell Therapy, Donor Lymphocyte Infusion, and Hematopoietic Progenitor Cell Collection","authors":"Rajat Bansal, Anthony Wiedel, Riley Hastings, Fred Boutz, Haitham Abdelhakim, Nausheen Ahmed, Muhammad Umair Mushtaq, Joseph McGuirk, Sunil Abhyankar","doi":"10.1002/jca.70004","DOIUrl":"10.1002/jca.70004","url":null,"abstract":"<div>\u0000 \u0000 <p>Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of adequate peripheral venous access. CVC placement has risks of associated complications and requires additional institutional resources and expertise. We present a single institutional experience with 78 patients, who underwent a total of 87 apheresis procedures after placement of a midline catheter. This included 49 individuals who collected cells for immune effector cell therapy. Apheresis through midline catheter was successful in 81 out of 87 procedures. There were no midline catheter associated thromboses or infections. Six patients required placement of a backup CVC and were able to undergo apheresis without delay. Our experience shows that use of midline catheter for apheresis is feasible and generalizable to most populations requiring cellular therapy, with the potential to decrease utilization of limited healthcare resources.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

I-JAMM (II)—Therapeutic Apheresis Practices in Preconditioning of ABO-Incompatible Kidney and Liver Transplants in India I-JAMM (II)-印度abo血型不相容肾和肝移植预处理中的治疗性采血实践。

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2024-12-22 DOI: 10.1002/jca.70003

Prashant Pandey, Arghyadeep Marik, Aseem Tiwari, Sudipta Shekhar Das, Shamee Shastry, Vivek Kute, Mohit Chowdhry, Supriya Kumari, Divya Setya

{"title":"I-JAMM (II)—Therapeutic Apheresis Practices in Preconditioning of ABO-Incompatible Kidney and Liver Transplants in India","authors":"Prashant Pandey, Arghyadeep Marik, Aseem Tiwari, Sudipta Shekhar Das, Shamee Shastry, Vivek Kute, Mohit Chowdhry, Supriya Kumari, Divya Setya","doi":"10.1002/jca.70003","DOIUrl":"10.1002/jca.70003","url":null,"abstract":"<div>\u0000 \u0000 <p>ABO-incompatible transplantations are increasingly gaining relevance with advancements in therapeutic modalities, thus allowing patients to receive timely solid organ transplants. Therapeutic apheresis (TA) procedures remain instrumental as a preconditioning measure to enable such transplants. This survey was undertaken to find out current trends and practices of TA across major transplant centers in India. The survey was drafted by a working group of transfusion and transplant immunology specialists from six different centers in India. Data were obtained via the use of an online questionnaire. Results were categorized into eight categories: hospital information, range of titers for preconditioning, considerations prior to starting TA, TA procedure details, role of pharmacotherapy in TA, policy for reuse of columns, risk of rebound, and the role of transfusion medicine specialists. The survey highlighted the modalities as well as the methodologies of various TA procedures used across different major transplant centers in India. With the increase in ABO-incompatible kidney and liver transplants across the country, the role of transfusion medicine and transplant immunology specialists have become vital in preconditioning regimes enabling the viability and success of such transplants. This was a unique survey that provided us a snapshot of current trends and practices of TA in preconditioning of patients for ABO-incompatible transplants in India.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 6","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Apheresis Knowledge: An Educational Intervention for Non-Apheresis Medical Providers 提高采血知识：对非采血医疗提供者的教育干预。

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2024-12-16 DOI: 10.1002/jca.70001

Robert Achram, E. Alexander Dent, Marianne Yee, John D. Roback, Jeannette Guarner, H. Cliff Sullivan

引用次数: 0

What's in a Name: Your PLEX or PEX Is Our TPE 名字的含义：您的 PLEX 或 PEX 就是我们的 TPE。

IF 1.4 4区医学

Journal of Clinical Apheresis Pub Date : 2024-12-16 DOI: 10.1002/jca.70000

Ziver Sahin, Aaron Christensen, Juliana Guarente, Angelica Vivero, Julie Katz Karp

引用次数: 0

Clotted Apheresis Hematopoietic Stem Cell Product 凝血分离造血干细胞产品。